This includes terminating awards and contracts with pharmaceutical companies and universities and canceling 22 investment projects worth nearly $500 million. While some final-stage contracts will be allowed to be completed, no new mRNA-based projects will be initiated, the HHS said.

That kind of shot was first used during the Covid-19 pandemic, but the health secretary has been sharply critical of the technology.